ROCKI Inhibitors as Anticancer Drugs

OCR Number: 
OCR 4662

ROCK1, or Rho kinase, is a protein kinase activated by Rho that plays a signaling role in cell morphology, transformation, motility, focal adhesion, and cytokinesis. Inhibition of this pathway may prevent tumor cell motility and metastasis. Novel small-molecule inhibitors of ROCK1 have been synthesized and assayed for activity in vitro, and are candidates as anti-cancer drugs.

Features and Benefits:

  • Novel compounds have been synthesized that exhibit strong inhibition of ROCK1, offering potentially high potency.
  • The synthetic routes are short and have high yields.
  • The inhibitors have improved selectivity for ROCK1 over other protein kinases, offering potential as superior targeted agents.
Licensing Contact: